Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection. Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; yet toxicity with this target remains high. DUBs (deubiquitinating enzymes) represent an alternative target in the UPS with low predicted toxicity. Currently, there are no DUB inhibitors that have been used clinically. To address this situation, Progenra has developed a novel assay to measure the proteolytic cleavage of Ub (ubiquitin) or UBL (Ub-like protein) conjugates such as SUMO (small Ub-related modifier), NEDD8 (neural-precursor-cell-expressed, developmentally down-regulated 8) or ISG15 (interferon-stimulated gene 15) by isopeptidases. In this review, current platforms for detecting DUB inhibitors are discussed and the advantages and disadvantages of the approaches are underlined.
Introduction
The conjugation of Ub (ubiquitin) and UBLs (Ub-like proteins) is an important regulatory mechanism that is widespread in many biological processes [1] . The assorted diseases associated with these pathways make the pathway enzymes particularly interesting for therapeutic targets. The UPS (Ub-proteasome system) has been validated following the approval of the proteasome inhibitor Bortezomib for the treatment of multiple myeloma; however, significant toxicities were seen during clinical trials, suggesting the need for more selective targets [2] . Ub-and UBL-isopeptidases represent a unique set of drug targets in the UPS that are responsible for removing Ub and UBLs, such as SUMO (small Ub-related modifier), NEDD8 (neural-precursorcell-expressed, developmentally down-regulated 8) and ISG15 (interferon-stimulated gene 15), from target proteins, thus affecting the targets' fate [3] . To develop therapeutic agents that target isopeptidases, we developed a readily quantifiable novel isopeptidase assay platform that is suitable for HTS (high-throughput screening). The assay platform consists of Ub or UBL fused to the reporter enzyme PLA 2 (phospholipase A 2 ) . Isopeptidase activity releases PLA 2 that cleaves its substrate, generating a signal that is linear with isopeptidase concentration and is able to discriminate DUB (deubiquitinating enzyme), deSUMOylase, deNEDDylase Key words: deISGylase, deNEDDylase, deSUMOylase, deubiquitinating enzyme (DUB), highthroughput screening (HTS), isopeptidase, small ubiquitin-related modifier (SUMO). Abbreviations used: DUB, deubiquitinating enzyme; FRET, fluorescence resonance energy transfer; HTS, high-throughput screening; ISG15, interferon-stimulated gene 15; NEDD8, neuralprecursor-cell-expressed, developmentally down-regulated 8; PLA2, phospholipase A2; RING, really interesting new gene; SCF, Skp1/cullin/F-box; Skp, S-phase kinase-associated protein; Ub, ubiquitin; SUMO, small Ub-related modifier; TRAF, tumour-necrosis-factor-receptor-associated factor; TR-FRET, time-resolved FRET; Ub-AMC, Ub-7-amino-4-methylcoumarin; UBL, Ub-like protein; UBP/USP, Ub-specific proteases; ULP, UBL-specific protease; UPS, Ub-proteasome system. 1 To whom correspondence should be addressed (email Goldenberg@progenra.com).
and deISGylase activities. The assay can be successfully employed to screen for inhibitors of isopeptidases.
Therapeutic targets in the UPS
The approval of the proteasome inhibitor Bortezomib (Velcade) for the treatment of multiple myeloma validated the targeting of the UPS for the treatment of cancer [4] . However, extended treatment with Bortezomib is associated with toxicity and drug resistance, limiting its efficacy [2] . In contrast, therapeutic strategies that target specific aspects of the UPS upstream of the proteasome would be predicted to have lower toxicity. While activating enzymes (E1) and conjugating enzymes (E2) are upstream of the proteasome, one must be aware of the consequences of targeting them, as disruption of the E1 leads to cell-cycle arrest [5] and E2s have been shown to be required for development [6] . Targeting the Ub-activating enzyme may be predicted to affect too many cellular functions for it to be tolerated by normal cells; yet targeting the NEDD8-activating enzyme for inhibition has been reported to be successful in preclinical studies [7] . The mechanism of action is most likely through inactivation of the cullin-based E3 ligases, many of which play a crucial role in cell-cycle checkpoints whose disruption would have a more immediate effect on rapidly dividing cancer cells.
E3 ligases, with only a limited number of substrates, represent attractive drug targets in the UPS. One of the most interesting E3 targets is SCF [Skp (S-phase kinase-associated protein) 1/cullin/F-box]. The SCF complex consists of many variable F-box adaptor proteins each of which target only a few substrates for ubiquitination [8] . Two therapeutically relevant F-box proteins are Skp2 [9] and β-TRCP (β-transducin repeat-containing protein) [10] , which play key roles in cell-cycle progression. However, to inhibit these proteins one must disrupt a protein-protein interaction, which is considered a more difficult target than an enzymatic target. [46] , HMWP (pUL48) [47] , PLP2 [48] Bacterial infection SseL [49] , ElaD [50] Isopeptidases identified to date have been grouped into five subfamilies. Four of these five families are cysteine proteases, which have been shown to be good therapeutic targets. The UCHs (Ub C-terminal hydrolases), UBP/USP (Ub-specific proteases), MJD (Machado-Joseph domain) and OTU (ovarian tumour-related) isopeptidases are cysteine proteases, whereas the JAMM (JAB1/MPN/Mov34 metalloenzyme) motif DUBs are Zn metaloproteases. A total of 90 putative DUBs have been identified with 79 most likely being functional. There are also many UBL-isopeptidases that are good therapeutic targets [3, 11] .
The role of DUBs and ULPs (UBL-specific proteases) in disease
Several isopeptidases have been implicated in disease [12] , in particular cancer (refer to Table 1 ). For example, USP7 [Ub-specific protease 7; also known as HAUSP (herpesvirusassociated Ub-specific protease)] regulates the ubiquitination state of the RING (really interesting new gene)-finger E3 ligase Mdm2 (murine double minute 2) (and its human homologue Hdm2) [13] . Hdm2 targets the tumour suppressor p53 for ubiquitination and facilitates its degradation by the proteasome [14, 15] . Many other RING-finger E3 ligases are capable of autoubiquitination; Hdm2 is no exception and autoubiquitinates resulting in its own proteolytic degradation [16] . However, Hdm2 also ubiquitinates p53, resulting in degradation of p53 via the proteasome. Initially, USP7 was believed to primarily deubiquitinate p53, increasing the level of p53 [17] . However, more recent genetic and biochemical studies have found that with respect to p53 and Hdm2, the primary target of USP7 is Hdm2 [13, 18] . These results were corroborated by structural biology studies which revealed that Hdm2 and p53 recognize the TRAF (tumour-necrosis-factor-receptor-associated factor) domain of USP7 in a mutually exclusive manner, but Hdm2 binds to the TRAF domain with a higher affinity than p53 [19] .
While DUBs have received the most attention, proteases that deconjugate UBLs from their target proteins have also been linked to various pathophysiologies, as they are critical to cellular localization, transcriptional regulation, signal transduction pathways and the regulation of some Ub E3 ligases [20] [21] [22] [23] [24] .
Current assay systems for DUBS and UBL-isopeptidases
Many assays currently in use rely on cleavage of linear Ub fusions, which can be produced in Escherichia coli [tetraUb, Ub-CEP52, Ub-GSTP1 (Ub-glutathione transferase P1), Ub-DHFR (Ub-dihydrofolate reductase), Ub-PESTc etc.] or synthesized chemically [25] [26] [27] . For small-scale analysis of isopeptidase activity, reaction products are analysed by gel electrophoresis, or are selectively precipitated and analysed by liquid-scintillation spectrometry. Gel-based procedures are labour-intensive and expensive, and, although scintillation-counting approaches are quantitative and allow processing of larger numbers of samples than gel-based assays, they require centrifugation and recovery of supernatant. For HTS, a fluorogenic substrate, Ub-AMC (Ub-7-amino-4-methylcoumarin), has been employed in some cases, as well as a similar substrate, the tetrapeptide Z (benzyloxycarbonyl)-LRGG-AMC, which mimics the C-terminus of Ub [28] . A limiting factor with both of these fluorescent substrates is the fact that this small adduct cannot be hydrolysed efficiently by the largest class of DUBs, UBP/USP class enzymes. Moreover, the excitation wavelength of Ub-AMC is in the UV range, which is known to excite a number of screening compounds and give rise to up to 20 % false positives [29] . FRET (fluorescence resonance energy transfer) has also been developed for HTS screens [30] . FRET, however, suffers from the need for specialized reagents and equipment, as well as from difficulty in adapting to a multiwell plate format from which the endpoints can be read directly. In many of these approaches, expensive double-labelled or tagged substrates must be generated specifically for each assay (refer to Table 2 for comparison of current technologies).
An improved paradigm for detection of DUB and UBL-isopeptidase inhibitors, the UBL-PLA 2 reporter assay
While isopeptidases have been of interest for some time, to our knowledge no compounds have entered clinical trials. One reason for this could be the assays employed in drug-discovery campaigns. All of the previously described platforms are based on Ub linked to small chemical adducts and are not related to the physiological target of most The UBL-PLA 2 assay is based on the concept that PLA 2 requires a free N-terminus to be catalytically active. PLA 2 cleaves phospholipids to produce lysophospholipids and non-esterified fatty acids and requires a free N-terminus for catalytic activity [31] . When PLA 2 is fused to a UBL, it is inactive and cannot cleave its substrate. When a DUB or other UBL-isopeptidase is present, it cleaves the UBL from PLA 2 , freeing PLA 2 to act on its substrate. There are a number of commercial substrates for PLA 2 including the fluorescent phospholipid β-BODIPY C 5 -HPC [2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine] and NBD C 6 -HPC {2- [6-(7- nitrobenz-2-oxa-1,3-diazol-4-yl) amino]hexanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine}. The fluorescence response produced by these substrates occurs over a wavelength range that is better suited for drug discovery than that employed in the Ub-AMC assay, and it is amplified by the coupling of DUB catalytic activity with PLA 2 , resulting in enhanced sensitivity. Importantly, the Ub/UBL-PLA 2 fusion proteins represent more physiological substrates than the short C-terminal adducts exemplified by the commercially available AMC or TR-FRET (time-resolved FRET) reagents.
Future of DUB therapies
To our knowledge, no DUB inhibitors have entered clinical trials. However, modulation of the DUB CYLD (cylindromatosis) pathway with aspirin has been shown to be therapeutically viable in humans [32, 33] . Progenra's proprietary assay technology has been used by multiple groups to screen more than 100 000 compounds to date, with that number expected to double by the end of 2008. Owing to the increasing screening that is being performed against isopeptidases by ourselves and other researchers, we anticipate that multiple DUB inhibitors will be used clinically in the near future.
